Market
Scenario:
The
global gastrointestinal stromal tumors market is expected to gain prominence
over the forecast period (2018–2023). It is estimated that the global
gastrointestinal stromal tumors market is expected to register at a CAGR ~ 7 %
during the forecast period of 2018–2023.
A
Gastrointestinal Stromal Tumor (GIST) is a type of tumor which occurs in the
gastrointestinal tract and most commonly in the stomach or small intestine.
These tumors grow from specialized cells found in the gastrointestinal tract
called Interstitial Cells of Cajal (ICC) or precursors to these cells. GIST
affects an estimated 11 to 20 patients per million per year worldwide.
GISTs are rare cancers known as
soft tissue sarcomas. These tissue sarcomas develop in supporting and
connective tissues. These GIST accounts for around 20% of soft tissue sarcomas
and is the most common mesenchymal tumors affecting the gastrointestinal tract.
Treatment of GIST is largely dependent on the size of the tumor, position, and
development rate, and is most commonly removed through the procedure of
surgical resection and targeted therapies.
The
growth of this market is due to increasing prevalence of gastrointestinal
diseases, increasing the prevalence of cancer, increasing investments and
funding in the field of life science research, increasing awareness among the
people, growing geriatric population, changing reimbursement policies and
various others.
However,
one of the major factors that hampered the growth of the gastrointestinal
stromal tumors is the presence of misbranded and spurious drugs.
Segmentation
The
global gastrointestinal stromal tumors market is segmented on the basis of the
indication, diagnosis, treatment, and end-user.
On the
basis of indication, the market is classified into stomach, small intestine,
large intestine (colon), and other indications.
On the
basis of diagnosis, the market is segmented into imaging studies, plain abdominal
radiography, barium and air (double-contrast) series, computed tomography scans
of the abdomen and pelvis, magnetic resonance imaging, endoscopy, endoscopic
ultrasonography, and others.
The
global gastrointestinal stromal tumors market on the basis of treatment is
segmented into surgery, targeted therapy, radiation therapy, chemotherapy,
ablation, embolization and others. Targeted therapy is further segmented into
Tyrosine kinase inhibitors (TKIs), Imatinib, Sunitinib, Regorafenib, and
others. While, ablation is segmented into Radiofrequency ablation (RFA),
ethanol (alcohol) ablation, microwave thermotherapy, cryosurgery (cryotherapy),
and others.
On the
basis of end-user, the global gastrointestinal stromal tumors market is
segmented into hospitals & clinics, ambulatory surgical centers, and
others.
Geographically,
the market has been segmented into America, Europe, Asia Pacific, and the
Middle East & Africa. The Americas gastrointestinal stromal tumors market
is further segmented into North America, and South America. North America is
further classified as the U.S. and Canada.
The
European gastrointestinal stromal tumors market is segmented into Western
Europe and Eastern Europe. Western Europe is further classified as Germany,
France, the U.K., Italy, Spain, and the Rest of Western Europe.
The Asia
Pacific gastrointestinal stromal tumors market is segmented into Japan, China,
India, Republic of Korea, Australia, and the Rest of Asia Pacific.
The
Middle East & Africa gastrointestinal stromal tumors market is segmented
into the Middle East and Africa.
Regional
Market Summary
Globally,
the American region is the largest market for gastrointestinal stromal tumors
owing to the increasing occurrence of liver cancer, the presence of major
manufacturers in the region, and the development for the products. Moreover,
increasing presence of genetic disorders in the U.S., robust healthcare
infrastructure, availability of exclusive medical facilitates for caretaking of
patients suffering from inoperable cancers will continue to drive the growth of
the American gastrointestinal stromal tumor market.
Europe
accounted for the second largest share in global gastrointestinal stromal
tumors market in 2017. Growing number of cases of gastrointestinal stromal
tumors is a major driving force of this market. Approximately 11 to 20 people
per million worldwide are diagnosed with GIST each year, and in Europe, there
are an estimated 15 people per million living with GIST.
Asia
Pacific is expected to be the fastest growing market for gastrointestinal
stromal tumors market owing to the developing healthcare facilities, increasing
awareness, and changing healthcare facilities. Moreover, major companies are
grabbing these opportunities and expanding their presence in the region. Furthermore,
increasing research and development in this region has further enhanced the
growth of the market.
The
Middle East & Africa also shows a steady rise in the market owing to
limited availability of medical facilities, and to the lack of knowledge in the
medical sector.
Key
Players
Some of
the key players in the global gastrointestinal stromal tumors market are
Bayer AG (Germany) Novartis AG (Switzerland), Immunicum AB (Sweden), F.
Hoffmann-La Roche Ltd.(Switzerland), AB SCIENCES (FRANCE), Arog Pharmaceuticals,
Inc. (U.S), Boston Biomedical, Inc. (U.S), Sun Pharmaceutical Industries
Limited (India), (U.S), Pfizer Inc. (U.S), and NATCO Pharma Limited (U.S), and
others.
Browse Complete 90 Pages Premium Research Report Enabled with 92
Respective Tables and Figures @ https://www.marketresearchfuture.com/reports/gastrointestinal-stromal-tumors-market-1583
Detailed Table
of Contents:
Chapter 1. Report Prologue
Chapter 2. Market
Introduction
2.1 Definition
2.2 Scope Of The Study
2.2.1 Research Objective
2.2.2 Assumptions
2.2.3 Limitations
Chapter 3. Research Methodology
3.1 Introduction
3.2 Primary Research
3.3 Secondary Research
3.4 Market Size Estimation
Chapter 4. Market Dynamics
4.1 Drivers
4.2 Restraints
4.3 Opportunities
4.4 Challenges
4.5 Macroeconomic Indicators
4.6 Technology Trends & Assessment
...Continued
About US:
Market
Research Future (MRFR), enable customers to unravel the complexity of various
industries through Cooked Research Report (CRR), Half-Cooked Research Reports
(HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market
Research & Consulting Services.
Contact
Us:
Market
Research Future
Office
No. 528, Amanora Chambers
Magarpatta
Road, Hadapsar,
Pune
- 411028
Maharashtra,
India
Phone:
+1 646 845 9312
Email:
sales@marketresearchfuture.com
No comments:
Post a Comment